SMC rejects Rupafin, Axorid and Depodur

The following drugs have been rejected by the Scottish Medicines Consortium (SMC) for use within NHS Scotland, as a result of absent or insufficient submissions from manufacturers:

  • Rupatadine (Rupafin) for allergic rhinitis and chronic idiopathic urticaria.
  • Ketoprofen/omeprazole (Axorid) for rheumatoid arthritis, ankylosing spondylitis and osteoarthritis in patients with a history or risk of NSAID-associated gastrointestinal ulceration or erosion.
  • Extended-release epidural morphine (Depodur) for relief of post-operative pain following major orthopaedic, abdominal or pelvic surgery.

The drugs may be subject to re-appraisal.

Further information: SMC

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases